New patent application by Small Pharma published today.
The “invention provides compositions and methods which enable a finely tuned single dose to maintain a patient in full dissociation from the external world, referred to herein as ‘DMT space.’”
1/
In particular, the invention takes advantage of “the kinetic isotope effect” exhibited by deuterated DMT analogs “in order to modify, controllably, the pharmacokinetic profile of N,N-DMT, thereby permitting more flexible therapeutic application.”
“Deuterated” means that one or more hydrogen atoms in DMT are replaced by its heavier stable isotope deuterium. Because of the “kinetic isotope effect,” deuterated drugs may have significantly lower rates of metabolism and a longer half-life.
Deuterated DMT reported to have longer duration of action & shorter time to onset “apparently due to kinetic isotope effect which, in theory, makes it harder for the MAO enzyme to extract a deuterium (vs a hydrogen) thus inhibiting degradation by MAO”